Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13942MR)

This product GTTS-WQ13942MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13942MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14462MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ13740MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ8947MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ2428MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ703MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ7118MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ3808MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ5346MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW